Liberia: Doctor Given Experimental Ebola Drug Dies

People with foodstuff for family members in the West Point area wait to be allowed into the area as Liberian soldiers control people from entering due to the fear of the Ebola virus spreading, in the city of Monrovi... People with foodstuff for family members in the West Point area wait to be allowed into the area as Liberian soldiers control people from entering due to the fear of the Ebola virus spreading, in the city of Monrovia, Liberia, Saturday, Aug. 23, 2014. The outbreak also continues to spread elsewhere in West Africa, with 142 more cases recorded, bringing the new total to 2,615 with 1,427 deaths, the World Health Organization said Friday. Most of the new cases are in Liberia, where the government was delivering donated rice to a slum where 50,000 people have been sealed off from the rest of the capital in an attempt to contain the outbreak. (AP Photo/Abbas Dulleh) MORE LESS
Start your day with TPM.
Sign up for the Morning Memo newsletter

MONROVIA, Liberia (AP) — A Liberian doctor who was among three Africans to receive an experimental Ebola drug has died, the country’s information minister said Monday.

Dr. Abraham Borbor, the deputy chief medical doctor at the country’s largest hospital, had been among three Liberians, and the first Africans, who received the drug, ZMapp. Two Americans received the untested drug and survived. A Spaniard infected with Ebola received the treatment but died. There was no update given on the two other Liberians who took doses of the drug.

Borbor “was showing signs of improvement but yesterday he took a turn for the worse,” Information Minister Lewis Brown told The Associated Press. It wasn’t clear if he died late Sunday or on Monday.

Ebola has killed more than 1,400 people across West Africa. There is no proven vaccine or cure for the disease that can cause a grisly death with bleeding from the eyes, mouth and ears.

The virus can only be transmitted through direct contact with the bodily fluids of the sick or from touching victims’ bodies, leaving doctors and other health care workers most vulnerable to contracting it.

Only six people in the world are known to have received ZMapp. The small supply is now said to be exhausted, and it is expected to be months before more can be produced by its U.S. maker.

Health experts caution that the drug had never been tested in humans before and it was unclear whether it works. They note there is a huge gap between the treatment the two Americans got at an Atlanta hospital, where five infectious disease experts and 21 nurses provided rigorous care, and West Africa, where even such basics as sterile fluids can be in short supply.

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Latest News
Comments
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: